Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R. Oxnard, Pasi A. Jänne, Yuebi Hu et al.|JAMA Oncology|2018Cited by 689
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibDaniel B. Costa, Keith D. Wilner|Journal of Clinical Oncology|2011Cited by 590
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerHiroyuki Yasuda, Daniel B. Costa, Wee-Lee Yeo et al.|Science Translational Medicine|2013Cited by 565
BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR MutationsDaniel B. Costa, Susumu Kobayashi|PLoS Medicine|2007Cited by 490
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerLecia V. Sequist, Joan H. Schiller, Joachim von Pawel et al.|Journal of Clinical Oncology|2011Cited by 379